Physician profile
Andrew Sun
NPI 1699235473
$16,537.66
in general payments reported to CMS, 2019-2025
30 companies · $6,154 in 2025
The $6,154 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $2,591 · 2024: $7,349 · 2025: $6,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,479 · Travel and Lodging: $7,614 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,478.63 |
| Travel and Lodging | $7,614.43 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,465.23 | 2024-2025 | Optis, Esprit, Supera |
| Boston Scientific Corporation | $3,293.82 | 2022-2025 | Ekosonic, Avvigo Guidance System, Watchman Flx |
| Edwards Lifesciences Corporation | $1,960.64 | 2024-2025 | Sapien 3 Ultra Resilia |
| Abiomed | $1,140.46 | 2023-2025 | Impella |
| Coloplast Corp | $1,114.29 | 2024-2025 | |
| Inari Medical, INC. | $497.74 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $381.18 | 2022-2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Pfizer INC. | $363.06 | 2022-2024 | |
| Teleflex LLC | $322.59 | 2025 | Turnpike, Guideliner, Trapliner |
| Actelion Pharmaceuticals US, INC. | $255.59 | 2024-2025 | Uptravi, Opsumit |
| Philips North America LLC | $225.49 | 2023 | |
| Cardiva Medical, INC. | $186.71 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Endo Pharmaceuticals INC. | $179.16 | 2023-2024 | Xiaflex |
| Bard Peripheral Vascular, INC. | $157.67 | 2024 | Venovo, Venclose Maven Catheter |
| Livanova USA, INC. | $151.69 | 2023 | Tandemheart |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $122.57 | 2024 | Xiaflex |
| Sanofi-Aventis U.S. LLC | $91.25 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $89.45 | 2023-2025 | Wainua, Farxiga |
| Amgen INC. | $83.91 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $73.54 | 2024-2025 | |
| Shockwave Medical, INC | $71.56 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Myovant Sciences INC. | $58.50 | 2022 | |
| Blue Earth Diagnostics | $46.95 | 2022 | |
| Sumitomo Pharma America, INC. | $42.96 | 2023 | Orgovyx |
| Kiniksa Pharmaceuticals, Ltd. | $40.94 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $32.56 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $26.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.59 | 2024 | Jardiance |
| Saranas, INC. | $20.64 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.